Gilead Sciences (GILD), Merck (MRK) Join Forces on Long-Acting HIV Therapy - WSJ

March 15, 2021 6:20 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Gilead Sciences (NASDAQ: GILD) and Merck (NYSE: MRK) are joining forces to develop a long-acting HIV therapy, according to the Wall Street Journal.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Hot Corp. News, Trader Talk